All In Biotech

Drug Trial Radar · NCT06976268

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

May 28, 2025

Primary completion

Aug 2027

Study completion Sep 2028

Sponsor

Lead sponsor
Biohaven Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
May 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.

Conditions

  • Parkinson Disease

Interventions

  • BHV-8000 10mgDrug

    taken orally

  • BHV-8000 20 mgDrug

    taken orally

  • PlaceboDrug

    taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first qualifying worsening event on Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IITime frame: Up to 48 Weeks

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Site-049

    Birmingham, Alabama · Recruiting

  • Site-079

    Sun City, Arizona · Recruiting

  • Site-003

    Irvine, California · Recruiting

  • Site-041

    Los Angeles, California · Recruiting

  • Site-025

    Aurora, Colorado · Recruiting

  • Site-031

    Farmington, Connecticut · Recruiting

  • Site-028

    New Haven, Connecticut · Recruiting

  • Site-038

    Atlantis, Florida · Recruiting

  • Site-017

    Boca Raton, Florida · Recruiting

  • Site-051

    Maitland, Florida · Recruiting

  • Site-027

    Chicago, Illinois · Recruiting

  • Site-029

    Kansas City, Kansas · Recruiting

  • Site-071

    Boston, Massachusetts · Recruiting

  • Site-004

    Foxborough, Massachusetts · Recruiting

  • Site-015

    Farmington Hills, Michigan · Recruiting

  • Site-044

    Chesterfield, Missouri · Recruiting

  • Site-006

    Albany, New York · Recruiting

  • Site-005

    New York, New York · Recruiting

  • Site-082

    Cleveland, Ohio · Recruiting

  • Site-091

    Portland, Oregon · Recruiting

  • Site-043

    Round Rock, Texas · Recruiting

  • Site-009

    Henrico, Virginia · Recruiting

  • Site-074

    Newport News, Virginia · Recruiting

  • Site-007

    Bellevue, Washington · Recruiting

  • Site-019

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.